

1 **Ultrarare Variants in DNA Damage Repair Genes in Pediatric Acute-Onset**
2 **Neuropsychiatric Syndrome or Acute Behavioral Regression in Neurodevelopmental**
3 **Disorders**

4
5 **Running title: DNA Damage Repair Genes in Acute Behavioral Regression**

6
7 Janet L. Cunningham¹, Jennifer Frankovich², Robert A. Dubin³, Erika Pedrosa⁴, Refia Nur
8 Baykara⁴, Noelle Cathleen Schlenk⁵, Shahina B. Maqbool⁶, Hedwig Dolstra⁴, Jacqueline
9 Marino⁴, Jacob Edinger⁴, Julia M. Shea⁴, Gonzalo Laje⁷, Sigrid M.A. Swagemakers⁸, Siamala
10 Sinnadurai^{8,9}, Peter J. van der Spek⁸, Herbert M. Lachman^{10*}

11
12 ¹Department of Medical Sciences, Psychiatry, Uppsala University, Uppsala, Sweden

13
14 ²Department of Pediatrics, Division of Pediatric Allergy, Immunology, Rheumatology and
15 Immune Behavioral Health Program, Stanford Children's Health and Stanford University School
16 of Medicine, Palo Alto, CA, USA

17 ³Center for Epigenomics / Computational Genomics Core, Albert Einstein College of Medicine

18 ⁴Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine.

19 ⁵Stanford Children's Health, PANS Clinic and Research Program, Stanford University School of
20 Medicine, Stanford, CA, USA.

21 ⁶Department of Genetics Epigenetics Shared Facility, Albert Einstein College of Medicine

22 ⁷Department of Psychiatry, Permian Basin, Texas Tech University Health Sciences Center
23 School of Medicine

24 ⁸Department of Pathology and Clinical Bioinformatics, Erasmus MC, Rotterdam, Netherlands

25 ⁹Department of Epidemiology and Health Promotion at the School of Public Health
26 Medical Center for Postgraduate Education, Warsaw, Poland

27 ¹⁰Department of Psychiatry and Behavioral Sciences, Department of Medicine, Department of
28 Genetics, Dominick P. Purpura Department of Neuroscience, Albert Einstein College of
29 Medicine

31 *corresponding author
32 Dr. Herbert Lachman
33 Albert Einstein College of Medicine
34 Forchheimer 103
35 1300 Morris Park Ave.
36 Bronx, New York 10461
37 Phone: 718-430-2428
38 Email: Herb.Lachman@einsteinmed.edu
39
40

41 **Abstract**

42 Acute onset of severe psychiatric symptoms or regression may occur in children with premorbid
43 neurodevelopmental disorders, although typically developing children can also be affected.
44 Infections or other stressors are likely triggers. The underlying causes are unclear, but a current
45 hypothesis suggests the convergence of genes that influence neuronal and immunological
46 function. We previously identified 11 genes in Pediatric Acute-Onset Neuropsychiatry Syndrome
47 (PANS), in which two classes of genes related to either synaptic function or the immune system
48 were found. Among the latter, three affect the DNA damage response (DDR): *PPM1D*, *CHK2*,
49 and *RAG1*. We now report an additional 17 cases with mutations in *PPM1D* and other DDR
50 genes in patients with acute onset of psychiatric symptoms and/or regression that were
51 classified by their clinicians as PANS or another inflammatory brain condition. The genes
52 include clusters affecting p53 DNA repair (*PPM1D*, *ATM*, *ATR*, *53BP1*, and *RMRP*), and the
53 Fanconi Anemia Complex (*FANCE*, *SLX4/FANCP*, *FANCA*, *FANCI*, and *FANCC*). We
54 hypothesize that defects in DNA repair genes, in the context of infection or other stressors,
55 could lead to an increase in cytosolic DNA in immune cells triggering DNA sensors, such as
56 cGAS-STING and AIM2 inflammasomes. These findings could lead to new treatment strategies.

58 **Introduction**

59 We recently reported the first whole exome and whole genome sequencing (WES and
60 WGS, respectively) analysis in Pediatric Acute-Onset Neuropsychiatry Syndrome (PANS) in
61 which ultrarare variants were found in 11 genes in 21 cases¹. The genes harboring ultrarare
62 variants (minor allele frequency <0.001) showed extensive heterogeneity but clustered to those
63 that affect innate and adaptive immunity; *PPM1D* (3 cases), *NLRC4* (4 cases), *RAG1* (3 cases),
64 *PLCG2*, and *CHK2*, or genes that affect synaptic function; *SGCE* (2 cases), *CACNA1B* (2
65 cases), *SHANK3* (3 cases), and one case each for *GRIN2A*, *GABRG2*, and *SYNGAP1*. Of the
66 21 subjects, five were diagnosed with autism spectrum disorder (ASD) before their deterioration
67 that met PANS criteria. In addition to ASD, four cases were diagnosed with another
68 neurodevelopmental disorder (NDD), one of whom had Jansen de Vries Syndrome (JdVS),
69 which is caused by truncating mutations in *PPM1D* exons 5 or 6 that cause a gain-of-function
70 effect by suppressing p53 and other proteins involved in the DNA damage repair response
71 (DDR) (e.g., *MDM2*, *ATM*, *CHK1*, *CHK2*, *ATR*, and *H2AX*)²⁻⁶. The high prevalence of PANS
72 superimposed on pre-existing NDD is consistent with the observations of other groups^{7, 8}.

73 PANS is thought to be an inflammatory disorder that primarily affects the deep brain grey
74 matter (primarily the basal ganglia but the thalamus and amygdala may be involved in more

75 extensive cases). This hypothesis is based on the cardinal symptoms of PANS and is supported
76 by four neuroimaging studies showing the following: swelling of the basal ganglia during the
77 acute stage, microglial activation in the caudate and globus pallidus, grey/white matter
78 differences in the basal ganglia, and microstructural changes throughout the brain but most
79 prominently in the basal ganglia⁹⁻¹².

80 The clinical diagnosis PANS has core symptoms of abrupt onset obsessive-compulsive
81 disorder (OCD) and/or restricted eating (food aversion), with two or more secondary symptoms:
82 anxiety, emotional lability, irritability, rage, cognitive regression, sleep disturbance, sensory
83 dysregulation, movement abnormalities, urinary symptoms including new onset dysuria or
84 urinary frequency¹³. While the criteria require 2 secondary symptoms, most patients have 5 to 6
85 secondary symptoms that start abruptly alongside the OCD and/or eating restriction. Autonomic
86 instability (POTS, dilated pupils, increased urinary frequency, enuresis) and hypermobility have
87 also been reported as co-morbid with PANS¹³⁻¹⁸. A deterioration in school performance occurs,
88 exemplified by the loss of previously learned skills and/or new onset procedural learning
89 challenges presumably relating to the basal ganglia inflammation PANS¹³⁻¹⁸. Activities of daily
90 living, extracurricular activities, and social interactions are severely affected during relapses.
91 PANS can occur in children with or without premorbid ASD or other NDD.

92 For parents, the abrupt onset is a telling feature with a rapid decline in behavior and
93 functioning that is sometimes, literally, overnight or emerging over a period of a week. The
94 course is typically relapsing and remitting, but not all relapses are hyperacute/acute. Relapses
95 are frequently associated with an infection and data in support of a neuroinflammatory etiology
96 for PANS is accumulating. In the subgroup of cases following Streptococcus infections, a range
97 of group A streptococcal (GAS) autoantibodies and antibodies to striatal cholinergic
98 interneurons can be detected^{15, 19-21}. Recently, an increased prevalence of folate receptor alpha
99 autoantibodies associated with cerebral folate deficiency and ASD were detected in PANS²².
100 Additionally, cross-sectional prevalence data show that approximately one-third of patients
101 meeting PANS criteria eventually develop enthesitis-related arthritis (ERA) and/or inflammatory
102 back pain further supporting a role for inflammation in this disorder^{18, 23}. Furthermore,
103 inflammatory/autoimmune disorders are prevalent in first-degree family members^{8, 24, 25}.

104 As is true in other rare pediatric rheumatological conditions (including ERA and
105 Sydenham chorea), observational studies in PANS suggest that non-steroidal anti-inflammatory
106 drugs (NSAIDs) and corticosteroids may alleviate symptoms and/or shorten the length of the
107 relapses²⁶⁻²⁸. More potent immunomodulators, such as intravenous immunoglobulin (IVIg) and a

108 B-cell inhibitor Rituximab have mixed results, likely due to the genetic heterogeneity and the
109 difficulty in appropriately powering randomized trials in relapsing/remitting conditions^{29, 30}.

110 An immune-based etiology is also suggested in some cases of ASD and NDD,
111 especially acute and subacute regression, which have some symptoms that overlap with PANS
112 and respond to immunomodulators³¹⁻³⁴. In addition, a strong family history of autoimmune
113 disorders is associated with an increased risk for ASD³⁵⁻³⁷.

114 We are interested in identifying genetic factors that underlie the development of PANS
115 and acute behavioral regression using next-generation sequencing. In our original paper, two of
116 the ultrarare variants we found are in genes that affect DDR (*PPM1D* and *CHK2*), and one
117 induces DNA breaks (*RAG1*). *RAG1*, along with *RAG2*, codes for endonucleases that induce
118 DNA double-strand breaks responsible for the somatic recombination that generates immune
119 cell diversity in B- and T-lymphocytes^{1, 38, 39}. *RAG1/RAG2* also affects NK cell differentiation and
120 plays a role in DNA transposition^{40, 41}. Double-stranded breaks induced by the RAG complex are
121 repaired by ATM, a serine/threonine kinase that orchestrates DNA repair at double-strand
122 breaks^{39, 42-44}.

123 Our overarching aim is to identify genetic variations that converge on common biological
124 pathways within the heterogeneous population of children with PANS or acute-onset regression
125 with or without premorbid NDD. Given the findings in our first PANS genetic study, one common
126 pathway is DNA repair. This hypothesis is supported by the findings in this paper in which many
127 other genes involved in DNA repair were identified that may contribute to genetic vulnerability.

128

129 **Subjects and Methods**

130 **Ethical considerations**

131 This study was conducted in accordance with the Declaration of Helsinki. Parents signed
132 informed consent approved by the Albert Einstein College of Medicine IRB (2022-14636).

133

134 **Subjects.** The subjects were identified through connections between the senior investigators
135 and a PANS group called EXPAND, a non-profit European advocacy organization for families of
136 children, adolescents, and adults with immune-mediated neuropsychiatric disorders
137 (<https://expand.care/>), through the Neuroimmune Foundation, a non-profit organization
138 dedicated to neuroimmune and inflammatory brain conditions (<https://neuroimmune.org/about/>),
139 The Louisa Adelynn Johnson Fund for Complex Disease
140 (<https://tlajfundforcomplexdisease.com/>), and the Jansen de Vries Syndrome Foundation
141 (<https://jansen-devries.org/>). Histories were obtained by the participating physicians and

142 confirmed and collated by one of the senior investigators who interviewed every family member
143 (H.M.L). The cases met the criteria for PANS with or without co-morbid ASD or NDD, or
144 individuals with ASD or other NDDs who had a history of rapid-onset behavioral regression.

145

146 **Genetic analyses**

147 Whole exome sequencing (WES) data was available for six cases (**Table**). WES was carried out
148 by different companies Courtagen Diagnostics Laboratory, GeneDx, Baylor Genetics, and for
149 case 10, WES was conducted locally in the Genetics Core at the Albert Einstein College of
150 Medicine, Epigenetics Shared Facility. For the remaining cases, data was available from
151 commercially available panels: Invitae (Primary Immunodeficiency Panel), NHS North West
152 (NDD panel). The genetic variants for cases 1 and 4-12 were verified using Sanger sequencing
153 (see **Table** and **Supplementary Methods**). A comprehensive description of the library
154 preparation and analysis of sequencing data for the Einstein sample (case 10) can be found in
155 the **Supplementary Methods** section. Parents were genotyped for variants found in all cases
156 except cases 10, and 13-16.

157

158 **Evaluation of Variants**

159 Minor allele frequencies (MAFs) were obtained from the GnomAD database on the UCSC
160 Genome Browser (<https://genome.ucsc.edu/>). The ClinVar database, Combined Annotation-
161 Dependent Depletion (CADD), and AlphaMissense were used to predict the pathogenicity of
162 mutations⁴⁵⁻⁴⁸. <https://www.ncbi.nlm.nih.gov/clinvar/>. RNAfold was used to predict the secondary
163 structure of RMRP. A detailed explanation is in the **Supplementary Methods** section.

164

165 **Results**

166 Ultrarare variants (MAF <0.001) affecting DNA repair genes were found in 17 cases (11 males
167 and 6 females; specific sex of cases are not included to maintain anonymity) including four
168 families with two or more affected individuals. The identified genes are involved in the p53 repair
169 pathway: *PPM1D* (2 cases), *ATM* (5 cases), *ATR* (2 cases), and *53BP1* (one case) (**Figure 1**),
170 and the Fanconi Anemia Complex (FC): *FANCE* (2 cases), *FANCP/SLX4* (2 cases), *FANCI*,
171 *FANCA*, and *FANCC* (one case each) (**Figure 2**; see **Table** for details on all p53 and FC gene
172 variants). The FC pathway repairs DNA interstrand crosslinks and interacts with ATM/ATR/p53
173 DNA repair pathways (**Figure 2**)⁴⁹⁻⁵⁴. In addition, ultrarare variants were found in 34 other
174 genes, many of which have effects on DNA repair and innate immune function (see
175 **Supplementary Table** for details on all additional variants described in this paper). STRING

176 was used to show the connections between the DNA repair genes and other variants found in
177 this study, which centered around ATM and p53 (**Figure 3**). The cases and genetic variants with
178 their potential impact on the phenotypes are described below.

179

180 **p53 DNA Repair Pathway (*PPM1D*, *ATM*, *ATR*, *53BP1*)**

181 **PPM1D (Protein phosphatase, Mg²⁺/Mn²⁺-dependent 1D)**

182 Case 1 has JdVS with a 1:1 mosaicism for a de novo truncating *PPM1D* variant in exon 6. The
183 patient was diagnosed with mild intellectual disability but was high functioning, requiring minimal
184 support until high school when the patient had an abrupt onset of OCD, anxiety, cognitive
185 regression, insomnia, and psychosis with rapid decline over approximately three weeks. The
186 deterioration coincided with an upper respiratory infection and post-infectious vasculitis. Further
187 regression occurred with the loss of previously mastered global abilities and the eventual
188 development of mutism, which has persisted for several years, unresponsive to psychiatric
189 medications and other clinical and behavioral interventions.

190 Two additional ultrarare de novo variants were found and are likely pathogenic, one of
191 which is relevant to the DDR hypothesis: a variant in *CSNK1a1*, which codes for Casein Kinase
192 1 Alpha 1, a p53 inhibitor^{55, 56}. Another was found in *SRPK3*, an SRSF Protein Kinase that has
193 no known effect on DDR, although interestingly, expression is inversely correlated with alpha-
194 synuclein levels in mouse models of Parkinson's disease⁵⁷. Finally, an inherited ultrarare,
195 nonsense mutation was found in the citrate transporter, *SLC13A5* as well as a splice acceptor
196 variant in *CACNA1S*.

197 Case 2 also has a typical JdVS variant (a truncating mutation in *PPM1D* exon 6) and
198 was diagnosed with ASD and a learning disability. The patient has periods of abrupt onset
199 behavioral regression lasting several days to months, characterized by eating refusal, rage,
200 cognitive deficits, loss of previously learned skills, an inability to walk, and enuresis. The most
201 severe relapses have occurred following infection with SARS-CoV2 and a Group A
202 Streptococcal infection concurrent with shingles.

203

204 **ATM (Ataxia-telangiectasia mutated or serine/threonine kinase)**

205 Case 3 carries an ultrarare and pathological frameshift mutation in *ATM*. The patient was
206 typically developing and excelled in school until adolescence when diagnosed with Postural
207 Orthostatic Tachycardia Syndrome (POTS), irritable bowel syndrome gastroparesis, and
208 enthesitis-related arthritis. Soon thereafter, an episode of gastroenteritis led to acute-onset
209 OCD, anxiety, impulsivity, and severe rage; the first of many such episodes. An MRI scan was

210 negative. Relapses responded to IVIg and steroid bursts; however, due to frequent relapses and
211 the development of chronic symptoms, a trial of Rituximab was undertaken, which was helpful.
212 While the patient appeared to respond to immunomodulation, severe symptoms returned when
213 these therapies were tapered or discontinued. Multiple hospitalizations for uncontrolled
214 psychiatric symptoms followed. A parent carries the same ATM variant and has a history of
215 dysautonomia and an inflammatory skin condition.

216 Other ultrarare variants found in this patient include a de novo variant in *AHNAK2* and
217 compound heterozygosity for two ultrarare *CACNA1H* variants. While there are no obvious
218 connections to DNA repair, *AHNAK2* has been implicated in systemic lupus erythematosus
219 (SLE) in two studies and *CACNA1H* mutations are found in ASD and intellectual disabilities⁵⁸⁻⁶¹.

220 Cases 4-7 are a family with four affected children who all carry a pathogenic parental
221 transmitted ATM splice donor mutation. There is a bilneal parental history of severe autoimmune
222 disorders and hypermobile joints, as well as an extended family history of early-onset cancer,
223 and autoimmune disorders. This is consistent with the increased risk of cancer and autoimmune
224 disorders in individuals with loss-of-function mutations in *ATM*⁶²⁻⁶⁵.

225 Case 4, the proband, was diagnosed with ASD and experienced a typical PANS
226 relapsing-remitting course with abrupt relapses of OCD, food aversion, anxiety, irritability,
227 impulse control problems, oppositional behaviors, tics, and fatigue. Relapses were commonly
228 coincident with infections and were effectively managed by addressing infections with antibiotics
229 and using IVIg. The proband also has a history of Hashimoto's thyroiditis, joint hypermobility,
230 and consistently low immunoglobulin levels which likely contributed to frequent infections.
231 Alongside the *ATM* variant, the patient inherited rare and ultrarare variants affecting DNA repair
232 and innate immunity including a likely pathogenic variant in *RNASEH2B*, which codes for
233 Ribonuclease H2, an enzyme that removes ribonucleotides that have been incorporated into
234 replicating DNA, affecting double-stranded break repair kinetics⁶⁶. Homozygosity for this variant
235 leads to Aicardi-Goutières syndrome (AGS), a type I interferonopathy characterized by
236 neurodevelopmental defects and upregulation of type I interferon signaling and
237 neuroinflammation due to the effects of DNA damage^{66, 67}. The patient also has ultrarare
238 nonsynonymous variants of unknown significance in *RAG2*, *NOD2*, and a 24-base pair
239 microduplication in *SP110*. Each of these genes has effects on innate immunity, but *RAG2* is the
240 only one with a strong connection to DNA repair, as described in the introduction^{1, 38, 39 68}. An
241 *NOD2* variant was transmitted from one of the parents. A second ultrarare variant in *NOD2* was
242 identified in the other parent (see **Supplementary Table**).

243 Cases 5-7 are siblings to case 4 who were all diagnosed with ASD, dysautonomia, and
244 joint hypermobility. They all have a relapsing-remitting course characterized by abrupt onset
245 OCD, anxiety, emotional lability, increased urinary frequency, oppositional behavior, and
246 reduced social interactions, along with cognitive and behavioral regression. Relapses are
247 typically coincident with infection. Case 5 had an MRI that showed right temporal sclerosis.
248 Cases 6 and 7 have epilepsy, low levels of IgM and IgA, and relapses improve after clearance
249 of infection and treatment with IVIg and/or a corticosteroid burst. Although they were not
250 analyzed by WES, each was analyzed by Sanger sequencing for the variants found in the
251 proband. Each sibling has inherited the *ATM* variant, and cases 5 and 6, the *RNASEH2B*
252 variant. They have also inherited one of the two *NOD2* variants.

253

254 **ATR (Ataxia telangiectasia and rad3-related protein)**

255 Cases 8 and 9 are siblings with regressive ASD and a relapsing-remitting course with relapses
256 commonly coincident with infections. They both have a unique, transmitted ultrarare *ATR* variant
257 of unknown significance. One parent has a history of Hashimoto's thyroiditis and a family history
258 of SLE, and the other parent has a history of joint hypermobility and childhood seizure disorder.
259 *ATR* is a serine/threonine kinase and DNA damage sensor that functions as a master regulator
260 of the DDR⁶⁹⁻⁷³. The proband, case 8, was a typically developing child with hypermobility who
261 was well until abrupt behavioral regression occurred following "croup" at which time a diagnosis
262 of ASD was made. The patient subsequently developed a relapsing-remitting course
263 characterized by abrupt onset OCD, aggression, and mutism. Relapses appeared to be
264 responsive to NSAIDs.

265 The proband's sibling, Case 9, was well until the development of an abrupt behavioral
266 regression and loss of previously achieved milestones following a herpesvirus 6 infection, after
267 which a diagnosis of ASD was made. The patient also has a relapsing-remitting course
268 characterized by abrupt onset of OCD, restricted eating, rage, and depression. Relapses are
269 typically coincident with infections. Symptoms typically respond to glucocorticoid bursts. MRI
270 showed atrophy of the hippocampus, amygdala, caudate, and putamen. WES analysis of both
271 cases 8 and 9 also revealed several other ultrarare variants of interest: *NLRX1*, *CENPJ*,
272 *CACNA1S*, *DBH*, and *CLPB*. The most interesting from the DNA repair perspective is a
273 pathogenic frameshift mutation in *CENPJ*, which codes for centromere protein J. Centromere
274 regulation is critical for maintaining genomic stability, and defects lead to aberrant mitosis and
275 activation of the cGAS-STING pathway^{73, 74}. It is interesting to note that biallelic mutations in
276 *CENPJ* and *ATR* can both cause Seckel syndrome, which is associated with cell-cycle

277 checkpoint signaling abnormalities^{75, 76}. Another variant was found in *NLRX1*, which codes for a
278 key player in the innate immune response that regulates NF- κ B expression and has been
279 implicated in autoimmune and inflammatory diseases⁷⁷⁻⁸⁰. A third sibling is typically developing
280 and did not inherit the *ATR* variant but carries the *CENPJ*, *CACNA1S*, and *CLPB* variants.
281 Thus, the two affected siblings with ASD and acute-onset neuropsychiatric symptoms have
282 ultrarare variants in two genes that affect DNA repair, *ATR*, and *CENPJ*, as well as *NLRX1*
283 *DBH*, *CACNA1S*, and *CLPB*.

284

285 **53BP1 (Tumor suppressor p53-binding protein 1)**

286 Case 10 has a history of developmental delay, and experienced severe regression as a young
287 child characterized by loss of the ability to walk, loss of verbal skills, and new-onset enuresis.
288 Upon WES, we found an ultrarare missense mutation in *53BP1*, a p53-binding protein that
289 regulates DDR⁸¹⁻⁸³. A preceding infection to initial deterioration was not ascertainable.
290 However, the patient developed a relapsing-remitting course with relapses (abrupt onset of
291 OCD, eating refusal, severe rage, and oppositional behavior) coincident with infections with
292 improvement following treatment infections with antibiotics. The patient also developed
293 Hashimoto's thyroiditis, scoliosis, joint hypermobility, and gastroparesis. A parent has a history
294 of Raynaud's and fibromyalgia, and there is a family history of thyroid disease and Parkinson's
295 Disease. Parents have not been genotyped. In addition to *53BP1*, several other ultrarare
296 variants were found that could be playing a role in the clinical state via DNA repair. One is
297 *MED1*, which codes for a mediator complex protein that plays a major role in homologous
298 recombination, base excision repair, the maintenance of genomic stability, and p53-dependant
299 apoptosis⁸⁴. It has also been implicated in SLE⁸⁵. Another is *KMT2D*, which codes for a histone
300 methyltransferase that plays a role in DNA repair and has been implicated in autoimmune
301 disorders^{86, 87}. Finally, we found a nonsense mutation in *MTO1*, which regulates oxidative
302 phosphorylation and has been found to affect DNA repair and recombination in yeast^{88, 89}.

303

304 **Fanconi Anemia Complex (FANCE, FANCP/SLX4, FANCA, FANCI, and FANCC)**

305 **FANCE (Fanconi anemia complementation group E)**

306 Cases 11 and 12, a sibling pair with common variable immune deficiency (CVID) and acute
307 onset of neuropsychiatric symptoms, both carry an ultrarare missense mutation in *FANCE*.
308 Case 11 met the diagnostic criteria for PANS, characterized by a relapsing-remitting course of
309 abrupt onset OCD, anxiety, and rage. Episodes were commonly coincident with group A
310 streptococcal infection and other infections and always improved after treating the infection

311 followed by a corticosteroid burst. IVIg (aimed to treat the underlying CVID) was associated with
312 a reduced frequency of relapses but did not reduce the severity of relapses. Case 12 was
313 diagnosed with ASD as a child after abrupt loss of speech and eye contact following an
314 infection. The patient regained eye contact and sociability, but apraxia of speech continued. He
315 regressed again later in childhood and soon thereafter was diagnosed with PANS, which was
316 characterized by abrupt onset of OCD, anxiety, aggression (self-injurious behavior and property
317 destruction), and tics. Symptoms improved after treating the infection followed by
318 corticosteroids. The patient subsequently developed acute onset dysarthria and mutism and
319 further evaluation revealed CSF pleocytosis, intracranial hypertension, and GAD antibodies
320 (three times the upper limit of normal). Subsequent relapses responded to addressing infection
321 followed by a corticosteroid burst. Relapse frequency (but not severity) was reduced following
322 the introduction of IVIg to treat CVID. Due to a chronic progressive course, Rituximab was
323 added, which was followed by documented improvements by the speech pathologist that were
324 lost when B cells were repopulated (the speech pathologist was blinded to treatments and B cell
325 repopulation). Consequently, Rituximab was scheduled quarterly. The clinical trajectory
326 improved but deteriorations coincident with infections occurred, so Leflunomide was added as
327 adjunct therapy which has led to further stabilization for 2 years. There is a positive history of
328 inflammatory skin disease on both sides of the family, and a family history of immunodeficiency
329 syndrome, arthritis, lupus-related autoantibodies, recurrent sepsis, and recurrent septic joints.
330 Both cases carry an ultrarare variant of unknown significance in *VPS13B*. Case 11 carries a
331 maternally transmitted *NOD2* variant that has been described as a risk allele in Crohn's
332 disease^{89,90}. Case 12 carries another ultrarare, pathogenic, novel variant involved in the DNA
333 repair gene, *THRAP3*, which codes for thyroid hormone receptor-associated protein 3, an RNA
334 processing factor involved in ATR kinase-dependent DDR and the expression of several DNA
335 repair proteins, including FANCL^{91,92}.

336

337 **FANCI (Fanconi anemia, complementation group I)**

338 Case 13 is a neurotypical child who developed a sudden onset of OCD, fatigue, restricted
339 eating, severe anxiety, enuresis, and insomnia following an upper respiratory infection.
340 Autoimmune thyroiditis was diagnosed based on having high titers of anti-thyroid peroxidase
341 and anti-thyroglobulin antibodies, an elevated TSH, and an ultrasound. A nonsense mutation in
342 *FANCI* was identified. There was a partial response to intravenous glucocorticoids, IVIg, and
343 Rituximab. Case 11 also carries ultrarare variants in two other genes that affect DNA repair.
344 One is a non-synonymous variant in another FC gene, *FANCP/SLX4*, which may be a benign

345 variant. However, cases 14 and 15 also have an ultrarare variant in this gene (see below). The
346 other is a variant in the DNA repair gene, *LIG4*, which codes for DNA Ligase IV, a key enzyme
347 involved in repairing DNA double-strand breaks through non-homologous end joining and
348 sealing DNA breaks that occur during V(D)J recombination^{93, 94}. *LIG4* mutations cause
349 autoimmune and immunodeficiency disorders^{94, 95}.

350

351 **FANCP/SLX4 Fanconi anemia, complementation group P/Structure-Specific** 352 **endonuclease subunit)**

353 Cases 14 and 15 are siblings diagnosed with CVID who carry a pathogenic mutation in
354 *TNFRSF13B*, which is one of the more common variants found in immune deficiencies^{96, 97}. The
355 same variant has been found in several other PANS cases (unpublished observations). They
356 also share an ultrarare variant in *FANCP/SLX4*, but the relatively low CADD score suggests that
357 the gene alone is not sufficient to explain the severe clinical presentation. Case 14 has a history
358 of acute neuropsychiatric decompensation consistent with PANS, who initially responded to
359 treatment with corticosteroid bursts and IVIg and further stabilized on Anakinra. Case 15 initially
360 presented with anxiety but has regressed substantially, developing a seizure disorder and
361 autoimmune encephalitis (AE) that has partially responded to Rituximab, glucocorticoids, and
362 IVIg. Anakinra has not been effective. MRI indicates atrophy. The siblings also have an ultrarare
363 missense mutation adjacent to a splice acceptor site in *DOCK8*, which has been implicated in
364 immune deficiency and autoimmune disorders^{64, 98}. Both also share a variant in *MEFV* (pyrin),
365 an inflammasome regulator gene that is commonly mutated in autoinflammatory disorders⁹⁹⁻¹⁰².
366 Finally, they both have an ultrarare variant in *RMRP*, a noncoding RNA that functions as the
367 RNA component of mitochondrial RNA processing endoribonuclease. This is a very intriguing
368 candidate according to our DNA repair model as it acts as an inhibitor of p53^{103, 104}. A
369 comparison between wild-type and mutant alleles using RNAfold shows differences in the
370 secondary structure, suggesting that it could be functional (**Supplementary Figure**).

371

372 **FANCA Fanconi Anemia, Complementation Group A**

373 Case 16 is a previously healthy and neurotypical child who presented with abrupt-onset OCD,
374 eating restriction, severe irritability, hyperactivity, aggression, mood swings, sensory
375 amplification, and headaches. Physical exam showed truncal instability, subtle choreiform
376 movements, folliculitis, and findings consistent with enthesitis and arthritis (confirmed on joint
377 ultrasound). Labs indicate persistently elevated vasculitis markers (high vWF Ag and D-dimers
378 after COVID-19), persistently elevated C4, and persistent microcytic anemia thought to be

379 secondary to chronic inflammation. The patient has had a secondary progressive course with
380 relapses coincident with infections (influenza, mycoplasma, COVID-19, and sinusitis) with partial
381 improvement after bacterial infections were treated. Psychotropics and CBT have been
382 minimally helpful. The patient did not tolerate oral or IV steroids, IVIg, or immunomodulation
383 aimed at treating arthritis and systemic inflammation (e.g., methotrexate, sulfasalazine, and
384 azathioprine). There has been a partial response to NSAIDs, and more recently, a solid
385 trajectory of improvement since introducing colchicine. An ultrarare pathogenic variant
386 (according to AlphaMissense) was found in *FANCA*. In addition, ultrarare variants were found in
387 five other genes that have effects on innate immune function, but no direct effect on DNA repair.
388 The most important is a pathogenic variant in *UNC93B1*, a regulator of nucleic acid-sensing toll-
389 like receptors (e.g., TLR3, TLR7, and TLR8) and interferon and STING signaling, suggesting a
390 synergistic interaction with *FANCA*-related DNA repair defects¹⁰⁵⁻¹⁰⁷. The others are ultrarare
391 variants of unknown significance in *NLRP1*, *TICAM1*, *TYK2*, and *TCN2*. *NLRP1*, *TICAM1*, and
392 *TYK2* have regulatory effects on the innate immune system, including nucleic acid sensing, and
393 have been implicated in autoimmune disorders¹⁰⁸⁻¹¹¹.

394 First-degree relatives have migraines, recurrent sinusitis, recurrent pancreatitis, and
395 spondylarthritis. First-degree family members also have anxiety, OCD, ADHD, and depression.

396

397 **FANCC Fanconi Anemia, Complementation Group C**

398 Case 17 had a typically developing childhood but developed OCD, ADHD, anxiety symptoms in
399 pre-school, followed by three significant deteriorations over the next couple of years resulting in
400 massive escalation of psychiatric symptoms - OCD, eating restriction, anxiety, irritability,
401 extreme levels of oppositionality, poor sleep, polyuria, school refusal, and refusal to engage in
402 basic routine personal care. Each deterioration resulted in prolonged absences from school and
403 uncontrollable behavior when able to attend. Treatment with an SSRI increased rage and
404 resulted in the emergence of suicidality, which led to the addition of a mood stabilizer.
405 Eventually, he was diagnosed with ASD. A medical work-up revealed: low C3, low C4, anti-
406 histone antibodies, microcytic anemia, livedo reticularis, enthesitis related arthritis, mild
407 proteinuria, sinusitis, and mild hypothyroidism. Treatment of suspected sinusitis followed by high
408 dose IVIg and a steroid burst resulted in a clear reduction in all psychiatric symptoms, the first
409 improvement seen in two years. Based on the arthritis diagnosis, and concern for relapse after
410 being weaned from steroids, the patient was started on standard of care for arthritis (NSAIDs,
411 methotrexate, sulfasalazine) and was able to return to school. Ongoing ADHD, OCD, and
412 anxiety, which have been relatively mild compared to previous levels, have been controlled with

413 pharmacological and behavioral therapy. There have been minor flares in psychiatric symptoms
414 and enthesitis after significant illnesses (e.g., flu, sinusitis) which are treated with standard-of-
415 care antibiotics for bacterial infections and early introduction of NSAIDs according to PANS
416 treatment guidelines. He has had no further major relapses and has become a good student
417 who is socially engaged at school and home. There is a history of acute rheumatic fever,
418 spondylarthritis, enthesitis related arthritis, psoriasis, and mood disorders in first degree
419 relatives. A pathogenic frameshift variant was found in *FANCC*. *FANCC* deficiency has been
420 found to mediate microglial pyroptosis and neuronal apoptosis in a mouse spinal cord contusion
421 model, and regulate mitophagy by interacting with Parkin^{112, 113}. Interestingly, we have identified
422 several PANS and regressive ASD cases with *PRKN* copy variants (unpublished observations).
423 Ultrarare variants were also found in *PARN*, and *IGLL1*, neither of which has significant direct
424 effects on DNA repair pathways, although *PARN*, which codes for Poly(A)-Specific
425 Ribonuclease, regulates mRNA 3' end cleavage reactions under DNA-damaging conditions¹¹⁴.
426 *IGLL1* is a regulator of B cell differentiation and deficiency leads to autosomal recessive
427 agammaglobulinemia^{115, 116}. Both variants were scored as benign according to AM, but the
428 CADD score for the *PARN* variant was 26.8 (**Supplementary Table**).

429

430 **Discussion**

431 Sixteen cases were identified with ultrarare variants in protein-coding genes related to p53 and
432 FC DNA repair pathways: *PPM1D*, *ATM*, *ATR*, *53BP1*, *FANCE*, *FANCI*, *FANCP/SLX4*, *FANCA*,
433 and *FANCC*. These were often accompanied by additional rare variants related to DNA repair
434 and/or immune deficiencies. Most individuals in this study have an underlying
435 neurodevelopmental disorder, with approximately half diagnosed with ASD. The unifying feature
436 for these cases is the distinct, acute onset change in behavior, severe psychiatric symptoms,
437 and loss of function in association with infections and other stressors. Many cases have
438 symptoms consistent with PANS, while others had acute, severe neuropsychiatric
439 decompensation (e.g., mutism, behavioral regression, loss of previously learned skills, cognitive
440 dysfunction) that did not meet clinical criteria for PANS. Co-morbid inflammatory conditions
441 were common, including vasculitis signs (n=2), enthesitis and/or arthritis (n=4), thyroiditis,
442 and/or elevated thyroid antibodies (n=3). Inflammatory conditions were also common among
443 first-degree family members. Three cases had abnormal MRI scans (cases 5, 9, and 15), and
444 one (case 3) had a normal study. Pleocytosis and moderately elevated anti-GAD antibodies
445 were found in case 12. Clinical improvement was observed in most cases following the
446 resolution of infections and the application of immunomodulation (NSAIDs, corticosteroids, IVIg,

447 Rituximab, colchicine, etc.). The findings are congruent with our previous work and provide
448 further support for our hypothesis that DNA repair deficits are a vulnerability factor for
449 neuropsychiatric decompensation.

450 The DNA repair hypothesis first emerged from our original genetic analysis in which
451 three out of the five immune genes we identified have strong connections to this process:
452 *PPM1D*, *CHK2*, and *RAG1*¹. The idea that DNA repair deficits underlie PANS and acute
453 decompensation in NDD is novel, although studies linking DDR to behavior have been
454 described. For example, postmitotic genome instability in neurons can lead to behavioral
455 alterations and neurodegenerative disorders, and genetic studies show that DNA repair genes
456 are involved in genetic subgroups of ASD and NDDs including most of the genes described in
457 this report (e.g., *PPM1D*, *ATM*, *ATR*, *53BP1*, *FANCE*, *FANCI*, and *FANCP/SLX4*)¹¹⁷⁻¹²⁴.

458 The two major gene families affecting DNA repair described in this paper code for
459 proteins involved in the p53 and FC pathways. So far, between the current study and our
460 previous report, we have found ultrarare variants in five protein-coding genes that directly affect
461 p53: *PPM1D*, *ATM*, *CHK2*, *ATR*, and *53BP1*. Among these genes, pathogenic mutations were
462 found in *PPM1D*, *ATM*, and, in our previous study, *CHK2*. The ultrarare *ATR* and *53BP1*
463 variants described in this paper, however, are variants of unknown significance that will require
464 replication and functional validation. Remarkably, we also found an ultrarare variant in the long
465 non-coding RNA gene, *RMRP*, a p53 inhibitor^{103, 104}. *RMRP* expression is induced by immune
466 activators and is increased in autoimmune/autoinflammatory disorders¹²⁵. As described in the
467 results section, structural differences between the mutant and wild-type alleles were predicted
468 by RNAfold, but again, functional validation would be needed to determine whether the *RMRP*
469 variant we identified affects p53 function and DNA repair.

470 Ultrarare variants were found in five different FC genes: *FANCE*, *FANCP/SLX4*, *FANCI*,
471 *FANCA*, and *FANCC*. Among these, all are predicted to be pathogenic, except the
472 *FANCP/SLX4* variants. However, the fact that two different ultrarare variants were found in this
473 gene in three cases from two families increases the likelihood they are playing a role.
474 Interestingly, FC proteins interact with components of the p53 DDR pathway, including ATM and
475 ATR (**Figure 2**)¹²⁶⁻¹²⁹.

476 Some researchers have suggested that autoimmune and/or autoinflammatory processes
477 underlie the development of behavioral regression in PANS and in a subgroup of individuals
478 with ASD^{34, 130-132}. Impaired DDR may be one mechanism for these associations as it can lead to
479 leakage of nuclear DNA into the cytosol, which can trigger the cGAS-STING pathway, a key
480 component of the type I interferon (IFN-I) anti-viral innate immune response, especially following

481 an infectious disease trigger^{65, 133-135}. Mitochondrial DNA breaks and oxidized mitochondrial DNA
482 released into the cytosol can also trigger cGAS-STING¹³⁶⁻¹³⁸. AIM2 inflammasome signaling,
483 which leads to the induction of IL-1 β and IL-18, is also triggered by cytosolic DNA^{139, 140}.

484 Physiological activation of cGAS-STING is central for the response to foreign viral DNA,
485 and perhaps viral RNA as well⁴⁰. However, studies show that over-activation can lead to
486 autoimmune, autoinflammatory, and neurodegenerative disorders¹⁴¹⁻¹⁴⁴. For example, increased
487 IFN-I responses mediated by cGAS-STING due to abnormal clearance of cytosolic DNA and
488 RNA have been implicated in the pathogenesis of autoimmune disorders including SLE and
489 aggressive rheumatoid arthritis¹⁴⁵⁻¹⁴⁸. Circulating type I IFN levels are elevated in approximately
490 50% of patients with SLE and IFN receptor inhibition is an approved therapy^{149, 150}. A substantial
491 fraction of SLE patients have neuropsychiatric symptoms^{151, 152}. It has also been proposed that
492 some neurodegenerative disorders involve cGAS-STING signaling, including Alzheimer's
493 Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Huntington's
494 disease (HD), and multiple sclerosis (MS)¹⁵³⁻¹⁵⁵. Markers for neurodegenerative disorders are
495 elevated in 27% of patients with psychiatric disease preselected for suspected immunological
496 involvement and phenotypes including catatonia, agitation, and acute onset of symptoms similar
497 to the cases described here, although the genetic data is not available
498 (<https://doi.org/10.21203/rs.3.rs-3491787/v1>). Early immunological interventions may mitigate
499 some damage, but this needs to be confirmed in clinical trials. However, other forms of damage
500 may accumulate over time that are not responsive to immunological interventions.

501 In addition to nuclear DNA, disruption of mitochondrial integrity can also lead to the
502 release of mitochondrial DNA into the cytoplasm, which is a potent cGAS-STING trigger¹³⁶⁻¹³⁸. A
503 few of the genes described in this report have effects on mitochondria (e.g., *MTO1*, *SLC13A5*,
504 *RMRP*). Some FC proteins also regulate mitochondrial DNA replication fork stability that can
505 activate the mtDNA-dependent cGAS/STING response when dysfunctional, and FANCI has
506 been found to regulate PRKN-mediated mitophagy^{156, 157}.

507 A large number of cases had more than one DNA repair gene mutation. This could be
508 due to ascertainment bias since most of the cases we studied had severe symptoms and
509 accompanying neurodevelopmental problems, which could have prompted genetic testing by
510 their physicians. Gene panels rather than WGS per se were performed in many cases, which
511 could cause ascertainment bias due to the selection of genes represented on the commercially
512 available gene panels (**Table**). However, the histories of autoimmune disorders from both
513 parents in many cases suggest true bilineal inheritance of risk variants.

- 547 8. O'Dor, S. L. *et al.* A Survey of Demographics, Symptom Course, Family History, and Barriers
548 to Treatment in Children with Pediatric Acute-Onset Neuropsychiatric Disorders and Pediatric
549 Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections. *J. Child*
550 *Adolesc. Psychopharmacol.* **32**, 476-487 (2022).
- 551 9. Giedd, J. N., Rapoport, J. L., Garvey, M. A., Perlmutter, S. & Swedo, S. E. MRI assessment
552 of children with obsessive-compulsive disorder or tics associated with streptococcal infection.
553 *Am. J. Psychiatry* **157**, 281-283 (2000).
- 554 10. Kumar, A., Williams, M. T. & Chugani, H. T. Evaluation of basal ganglia and thalamic
555 inflammation in children with pediatric autoimmune neuropsychiatric disorders associated with
556 streptococcal infection and tourette syndrome: a positron emission tomographic (PET) study
557 using ¹¹C-[R]-PK11195. *J. Child Neurol.* **30**, 749-756 (2015).
- 558 11. Cabrera, B. *et al.* Neuroanatomical features and its usefulness in classification of patients
559 with PANDAS. *CNS Spectr.* **24**, 533-543 (2019).
- 560 12. Zheng, J. *et al.* Association of Pediatric Acute-Onset Neuropsychiatric Syndrome With
561 Microstructural Differences in Brain Regions Detected via Diffusion-Weighted Magnetic
562 Resonance Imaging. *JAMA Netw. Open* **3**, e204063 (2020).
- 563 13. Chang, K. *et al.* Clinical evaluation of youth with pediatric acute-onset neuropsychiatric
564 syndrome (PANS): recommendations from the 2013 PANS Consensus Conference. *J. Child*
565 *Adolesc. Psychopharmacol.* **25**, 3-13 (2015).
- 566 14. Vreeland, A. *et al.* Neuroinflammation in Obsessive-Compulsive Disorder: Sydenham
567 Chorea, Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal
568 Infections, and Pediatric Acute Onset Neuropsychiatric Syndrome. *Psychiatr. Clin. North Am.*
569 **46**, 69-88 (2023).
- 570 15. Vreeland, A. *et al.* Post-infectious inflammation, autoimmunity, and OCD: Sydenham
571 Chorea, Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal
572 infection (PANDAS), and Pediatric Acute-onset Neuropsychiatric Disorder (PANS). *Dev.*
573 *Neurosci.* (2023).
- 574 16. Thienemann, M. *et al.* Clinical Management of Pediatric Acute-Onset Neuropsychiatric
575 Syndrome: Part I-Psychiatric and Behavioral Interventions. *J. Child Adolesc. Psychopharmacol.*
576 **27**, 566-573 (2017).
- 577 17. Chan, A. *et al.* Children With PANS May Manifest POTS. *Front. Neurol.* **13**, 819636 (2022).
- 578 18. Ma, M. *et al.* Arthritis in children with psychiatric deteriorations: a case series. *Dev.*
579 *Neurosci.*, 1 (2023).
- 580 19. Swedo, S. E. *et al.* Pediatric autoimmune neuropsychiatric disorders associated with
581 streptococcal infections: clinical description of the first 50 cases. *Am. J. Psychiatry* **155**, 264-271
582 (1998).

- 583 20. Cunningham, M. W. Molecular Mimicry, Autoimmunity, and Infection: The Cross-Reactive
584 Antigens of Group A Streptococci and their Sequelae. *Microbiol. Spectr.* **7**,
585 10.1128/microbiolspec.GPP3-2018 (2019).
- 586 21. Hyman, S. E. PANDAS: Too Narrow a View of the Neuroimmune Landscape. *Am. J.*
587 *Psychiatry* **178**, 5-7 (2021).
- 588 22. Wells, L., O'Hara, N., Frye, R. E., Hullavard, N. & Smith, E. Folate Receptor Alpha
589 Autoantibodies in the Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) and Pediatric
590 Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS)
591 Population. *Journal of personalized medicine* **14**, 166 (2024).
- 592 23. Frankovich, J. *et al.* Multidisciplinary clinic dedicated to treating youth with pediatric acute-
593 onset neuropsychiatric syndrome: presenting characteristics of the first 47 consecutive patients.
594 *J. Child Adolesc. Psychopharmacol.* **25**, 38-47 (2015).
- 595 24. Masterson, E. E. & Gavin, J. M. Baseline characteristics of children in the International
596 PANS Registry (IPR) Epidemiology Study. *BMJ Open* **14**, e072743-072743 (2024).
- 597 25. Chan, A. *et al.* Familial Clustering of Immune-Mediated Diseases in Children with Abrupt-
598 Onset Obsessive Compulsive Disorder. *J. Child Adolesc. Psychopharmacol.* **30**, 345-346
599 (2020).
- 600 26. Brown, K. *et al.* Pediatric Acute-Onset Neuropsychiatric Syndrome Response to Oral
601 Corticosteroid Bursts: An Observational Study of Patients in an Academic Community-Based
602 PANS Clinic. *J. Child Adolesc. Psychopharmacol.* **27**, 629-639 (2017).
- 603 27. Brown, K. D. *et al.* Effect of Early and Prophylactic Nonsteroidal Anti-Inflammatory Drugs on
604 Flare Duration in Pediatric Acute-Onset Neuropsychiatric Syndrome: An Observational Study of
605 Patients Followed by an Academic Community-Based Pediatric Acute-Onset Neuropsychiatric
606 Syndrome Clinic. *J. Child Adolesc. Psychopharmacol.* **27**, 619-628 (2017).
- 607 28. Spartz, E. J. *et al.* Course of Neuropsychiatric Symptoms After Introduction and Removal of
608 Nonsteroidal Anti-Inflammatory Drugs: A Pediatric Observational Study. *J. Child Adolesc.*
609 *Psychopharmacol.* **27**, 652-659 (2017).
- 610 29. Perlmutter, S. J. *et al.* Therapeutic plasma exchange and intravenous immunoglobulin for
611 obsessive-compulsive disorder and tic disorders in childhood. *Lancet* **354**, 1153-1158 (1999).
- 612 30. Williams, K. A. *et al.* Randomized, Controlled Trial of Intravenous Immunoglobulin for
613 Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections. *J.*
614 *Am. Acad. Child Adolesc. Psychiatry* **55**, 860-867.e2 (2016).
- 615 31. Hart, S. J., Worley, G., Kishnani, P. S. & Van Mater, H. Case Report: Improvement
616 Following Immunotherapy in an Individual With Seronegative Down Syndrome Disintegrative
617 Disorder. *Front. Neurol.* **12**, 621637 (2021).

- 618 32. Bey, A. L. *et al.* Subacute Neuropsychiatric Syndrome in Girls With SHANK3 Mutations
619 Responds to Immunomodulation. *Pediatrics* **145**, e20191490. doi: 10.1542/peds.2019-1490
620 (2020).
- 621 33. Zheng, J. *et al.* Association of Pediatric Acute-Onset Neuropsychiatric Syndrome With
622 Microstructural Differences in Brain Regions Detected via Diffusion-Weighted Magnetic
623 Resonance Imaging. *JAMA Netw. Open* **3**, e204063 (2020).
- 624 34. Malek, M. *et al.* Prednisolone as Adjunctive Treatment to Risperidone in Children With
625 Regressive Type of Autism Spectrum Disorder: A Randomized, Placebo-Controlled Trial. *Clin.*
626 *Neuropharmacol.* **43**, 39-45 (2020).
- 627 35. Mohebalizadeh, M. *et al.* Role of Maternal Immune Factors in Neuroimmunology of Brain
628 Development. *Mol. Neurobiol.* (2023).
- 629 36. Croen, L. A. *et al.* Family history of immune conditions and autism spectrum and
630 developmental disorders: Findings from the study to explore early development. *Autism Res.*
631 **12**, 123-135 (2019).
- 632 37. Arenella, M. *et al.* Immunogenetics of autism spectrum disorder: A systematic literature
633 review. *Brain Behav. Immun.* **114**, 488-499 (2023).
- 634 38. Braams, M., Pike-Overzet, K. & Staal, F. J. T. The recombinase activating genes: architects
635 of immune diversity during lymphocyte development. *Front. Immunol.* **14**, 1210818 (2023).
- 636 39. Christie, S. M., Fijen, C. & Rothenberg, E. V(D)J Recombination: Recent Insights in
637 Formation of the Recombinase Complex and Recruitment of DNA Repair Machinery. *Front.*
638 *Cell. Dev. Biol.* **10**, 886718 (2022).
- 639 40. Ni, G., Ma, Z. & Damania, B. cGAS and STING: At the intersection of DNA and RNA virus-
640 sensing networks. *PLoS Pathog.* **14**, e1007148 (2018).
- 641 41. Chen, X. *et al.* How mouse RAG recombinase avoids DNA transposition. *Nat. Struct. Mol.*
642 *Biol.* **27**, 127-133 (2020).
- 643 42. Helmink, B. A. & Sleckman, B. P. The response to and repair of RAG-mediated DNA
644 double-strand breaks. *Annu. Rev. Immunol.* **30**, 175-202 (2012).
- 645 43. Johnston, R. *et al.* Nuclease-independent functions of RAG1 direct distinct DNA damage
646 responses in B cells. *EMBO Rep.*, e55429 (2022).
- 647 44. Chu, S. H. *et al.* Loss of H3K36 Methyltransferase SETD2 Impairs V(D)J Recombination
648 during Lymphoid Development. *iScience* **23**, 100941 (2020).
- 649 45. Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD: predicting the
650 deleteriousness of variants throughout the human genome. *Nucleic Acids Res.* **47**, D886-D894
651 (2019).

- 652 46. Niroula, A. & Vihinen, M. How good are pathogenicity predictors in detecting benign
653 variants? *PLoS Comput. Biol.* **15**, e1006481 (2019).
- 654 47. Kircher, M. *et al.* A general framework for estimating the relative pathogenicity of human
655 genetic variants. *Nat. Genet.* **46**, 310-315 (2014).
- 656 48. Cheng, J. *et al.* Accurate proteome-wide missense variant effect prediction with
657 AlphaMissense. *Science* **381**, eadg7492 (2023).
- 658 49. Ceccaldi, R., Sarangi, P. & D'Andrea, A. D. The Fanconi anaemia pathway: new players and
659 new functions. *Nat. Rev. Mol. Cell Biol.* **17**, 337-349 (2016).
- 660 50. Jones, M. J. K. & Huang, T. T. The Fanconi anemia pathway in replication stress and DNA
661 crosslink repair. *Cell Mol. Life Sci.* **69**, 3963-3974 (2012).
- 662 51. Traband, E. L. *et al.* Mitotic DNA Synthesis in Untransformed Human Cells Preserves
663 Common Fragile Site Stability via a FANCD2-Driven Mechanism That Requires HELQ. *J. Mol.*
664 *Biol.* **435**, 168294 (2023).
- 665 52. Bona, N. & Crossan, G. P. Fanconi anemia DNA crosslink repair factors protect against
666 LINE-1 retrotransposition during mouse development. *Nat. Struct. Mol. Biol.* (2023).
- 667 53. Kupculak, M. *et al.* Phosphorylation by ATR triggers FANCD2 chromatin loading and
668 activates the Fanconi anemia pathway. *Cell. Rep.* **42**, 112721 (2023).
- 669 54. Alcón, P. *et al.* FANCD2-FANCI is a clamp stabilized on DNA by monoubiquitination of
670 FANCD2 during DNA repair. *Nat. Struct. Mol. Biol.* **27**, 240-248 (2020).
- 671 55. Xu, W. *et al.* Casein kinase 1 α inhibits p53 downstream of MDM2-mediated autophagy and
672 apoptosis in acute myeloid leukemia. *Oncol. Rep.* **44**, 1895-1904 (2020).
- 673 56. Liu, X. *et al.* Tumor-derived CK1 α mutations enhance MDMX inhibition of p53. *Oncogene*
674 **39**, 176-186 (2020).
- 675 57. Seo, M. H. & Yeo, S. Association Between Decreased Srpk3 Expression and Increased
676 Substantia Nigra Alpha-Synuclein Level in an MPTP-Induced Parkinson's Disease Mouse
677 Model. *Mol. Neurobiol.* **60**, 780-788 (2023).
- 678 58. Akizuki, S. *et al.* PLD4 is a genetic determinant to systemic lupus erythematosus and
679 involved in murine autoimmune phenotypes. *Ann. Rheum. Dis.* **78**, 509-518 (2019).
- 680 59. Wen, L. *et al.* Exome-wide association study identifies four novel loci for systemic lupus
681 erythematosus in Han Chinese population. *Ann. Rheum. Dis.* **77**, 417-211823. Epub 2017 Dec
682 12 (2018).
- 683 60. Kessi, M. *et al.* Calcium channelopathies and intellectual disability: a systematic review.
684 *Orphanet J. Rare Dis.* **16**, 219-0 (2021).

- 685 61. Viggiano, M. *et al.* Contribution of CACNA1H Variants in Autism Spectrum Disorder
686 Susceptibility. *Front. Psychiatry*. **13**, 858238 (2022).
- 687 62. Woodward, E. R. *et al.* Germline testing of BRCA1, BRCA2, PALB2 and CHEK2 c.1100delC
688 in 1514 triple negative familial and isolated breast cancers from a single centre, with extended
689 testing of ATM, RAD51C and RAD51D in over 400. *J. Med. Genet.* (2023).
- 690 63. Stubbins, R. J., Korotev, S. & Godley, L. A. Germline CHEK2 and ATM Variants in Myeloid
691 and Other Hematopoietic Malignancies. *Curr. Hematol. Malig Rep.* **17**, 94-104 (2022).
- 692 64. Azizi, G. *et al.* The Autoimmune Manifestations in Patients with Genetic Defects in the B Cell
693 Development and Differentiation Stages. *J. Clin. Immunol.* **43**, 819-834 (2023).
- 694 65. Pezone, A. *et al.* Inflammation and DNA damage: cause, effect or both. *Nat. Rev.*
695 *Rheumatol.* **19**, 200-211 (2023).
- 696 66. Ghosh, D., Kumari, S. & Raghavan, S. C. Depletion of RNASEH2 Activity Leads to
697 Accumulation of DNA Double-strand Breaks and Reduced Cellular Survivability in T Cell
698 Leukemia. *J. Mol. Biol.* **434**, 167617 (2022).
- 699 67. Viguera-Elías, D., de la Iglesia-Nagore, I., Toledo-Gotor, C., Domínguez-Garrido, E. & Poch-
700 Olivé, M. L. Aicardi-Goutieres syndrome: a family case due to alteration of the RNASEH2B
701 gene. *Rev. Neurol.* **72**, 407-409 (2021).
- 702 68. Walia, J. & Mujahid, R. Clinical Disease States Related to Mutations of the NOD2 Gene: A
703 Case Report and Literature Review. *Cureus* **15**, e38584 (2023).
- 704 69. Priya, B., Ravi, S. & Kirubakaran, S. Targeting ATM and ATR for cancer therapeutics:
705 Inhibitors in clinic. *Drug Discov. Today* **28**, 103662 (2023).
- 706 70. Maréchal, A. & Zou, L. DNA damage sensing by the ATM and ATR kinases. *Cold Spring*
707 *Harb Perspect. Biol.* **5**, a012716. doi: 10.1101/cshperspect.a012716 (2013).
- 708 71. Saxena, S. & Zou, L. Hallmarks of DNA replication stress. *Mol. Cell* **82**, 2298-2314 (2022).
- 709 72. Paull, T. T. Mechanisms of ATM Activation. *Annu. Rev. Biochem.* **84**, 711-738 (2015).
- 710 73. Lee, J. & Paull, T. T. Activation and regulation of ATM kinase activity in response to DNA
711 double-strand breaks. *Oncogene* **26**, 7741-7748 (2007).
- 712 74. Huang, Y. *et al.* DNAJA2 deficiency activates cGAS-STING pathway via the induction of
713 aberrant mitosis and chromosome instability. *Nat. Commun.* **14**, 5246-0 (2023).
- 714 75. Brown, A. D. *et al.* ATR suppresses endogenous DNA damage and allows completion of
715 homologous recombination repair. *PLoS One* **9**, e91222 (2014).
- 716 76. McIntyre, R. E. *et al.* Disruption of mouse Cenpj, a regulator of centriole biogenesis,
717 phenocopies Seckel syndrome. *PLoS Genet.* **8**, e1003022 (2012).

- 718 77. Nagai-Singer, M. A., Morrison, H. A. & Allen, I. C. NLRX1 Is a Multifaceted and Enigmatic
719 Regulator of Immune System Function. *Front. Immunol.* **10**, 2419 (2019).
- 720 78. Chen, L., Cao, S., Lin, Z., He, S. & Zuo, J. NOD-like receptors in autoimmune diseases.
721 *Acta Pharmacol. Sin.* **42**, 1742-1756 (2021).
- 722 79. Liu, M. *et al.* The regulatory role of NLRX1 in innate immunity and human disease. *Cytokine*
723 **160**, 156055 (2022).
- 724 80. Chu, X., Wu, S. & Raju, R. NLRX1 Regulation Following Acute Mitochondrial Injury. *Front.*
725 *Immunol.* **10**, 2431 (2019).
- 726 81. Leriche, M. *et al.* 53BP1 interacts with the RNA primer from Okazaki fragments to support
727 their processing during unperturbed DNA replication. *Cell. Rep.* **42**, 113412 (2023).
- 728 82. Arnould, C. *et al.* Chromatin compartmentalization regulates the response to DNA damage.
729 *Nature* **623**, 183-192 (2023).
- 730 83. Vincendeau, E. *et al.* SHLD1 is dispensable for 53BP1-dependent V(D)J recombination but
731 critical for productive class switch recombination. *Nat. Commun.* **13**, 3707-3 (2022).
- 732 84. Honjoh, H. *et al.* MED1, a novel binding partner of BRCA1, regulates homologous
733 recombination and R-loop processing. *Sci. Rep.* **12**, 17140-8 (2022).
- 734 85. Armstrong, D. L. *et al.* GWAS identifies novel SLE susceptibility genes and explains the
735 association of the HLA region. *Genes Immun.* **15**, 347-354 (2014).
- 736 86. Adam, M. P., Hudgins, L. & Hannibal, M. in *GeneReviews*(®) (ed Adam, M. P. *et al.*)
737 (University of Washington, Seattle. GeneReviews is a registered trademark of the University of
738 Washington, Seattle. All rights reserved, Seattle (WA), 1993).
- 739 87. Dermawan, J. K. *et al.* Distinct genomic landscapes in radiation-associated angiosarcoma
740 compared with other radiation-associated sarcoma histologies. *J. Pathol.* **260**, 465-477 (2023).
- 741 88. Zhurinsky, J. *et al.* Effects of the microtubule nucleator Mto1 on chromosomal movement,
742 DNA repair, and sister chromatid cohesion in fission yeast. *Mol. Biol. Cell* **30**, 2695-2708 (2019).
- 743 89. Zhou, C. *et al.* Clinical and genetic analysis of combined oxidative phosphorylation
744 deficiency-10 caused by MTO1 mutation. *Clin. Chim. Acta* **526**, 74-80 (2022).
- 745 90. Mushtaq Hashim Al-Bdere, N., Faaz Nassir Al-Saad, N., Jawad Al-Imari, M., Mudhafer
746 Habbeb, S. & Mizal Azoz, A. Genetic Polymorphisms of NOD2 and ATG16L1 in Different Types
747 of Digestive Tract Inflammation. *Arch. Razi Inst.* **78**, 493-498 (2023).
- 748 91. Vohhodina, J. *et al.* The RNA processing factors THRAP3 and BCLAF1 promote the DNA
749 damage response through selective mRNA splicing and nuclear export. *Nucleic Acids Res.* **45**,
750 12816-12833 (2017).

- 751 92. Beli, P. *et al.* Proteomic investigations reveal a role for RNA processing factor THRAP3 in
752 the DNA damage response. *Mol. Cell* **46**, 212-225 (2012).
- 753 93. Kumari, N., Antil, H., Kumari, S. & Raghavan, S. C. Deficiency of ligase IV leads to reduced
754 NHEJ, accumulation of DNA damage, and can sensitize cells to cancer therapeutics. *Genomics*
755 **115**, 110731 (2023).
- 756 94. Jauch, A. J. *et al.* Autoimmunity and immunodeficiency associated with monoallelic LIG4
757 mutations via haploinsufficiency. *J. Allergy Clin. Immunol.* **152**, 500-516 (2023).
- 758 95. Yilmaz Demirdag, Y. & Gupta, S. Infections in DNA Repair Defects. *Pathogens* **12**, 440. doi:
759 10.3390/pathogens12030440 (2023).
- 760 96. Ramirez, N. *et al.* Multi-omics analysis of naïve B cells of patients harboring the C104R
761 mutation in TACI. *Front. Immunol.* **13**, 938240 (2022).
- 762 97. Kakkas, I. *et al.* TACI Mutations in Primary Antibody Deficiencies: A Nationwide Study in
763 Greece. *Medicina (Kaunas)* **57**, 827. doi: 10.3390/medicina57080827 (2021).
- 764 98. de Valles-Ibáñez, G. *et al.* Evaluating the Genetics of Common Variable Immunodeficiency:
765 Monogenetic Model and Beyond. *Front. Immunol.* **9**, 636 (2018).
- 766 99. Nomani, H. *et al.* Implications of combined NOD2 and other gene mutations in
767 autoinflammatory diseases. *Front. Immunol.* **14**, 1265404 (2023).
- 768 100. Karamanakos, A. *et al.* Autoinflammatory syndromes with coexisting variants in
769 Mediterranean FeVer and other genes: Utility of multiple gene screening and the possible
770 impact of gene dosage. *Semin. Arthritis Rheum.* **56**, 152055 (2022).
- 771 101. Wouters, F., Bogie, J., Wullaert, A. & van der Hilst, J. Recent Insights in Pyrin
772 Inflammasome Activation: Identifying Potential Novel Therapeutic Approaches in Pyrin-
773 Associated Autoinflammatory Syndromes. *J. Clin. Immunol.* **44**, 8-5 (2023).
- 774 102. Nomani, H. *et al.* Implications of combined NOD2 and other gene mutations in
775 autoinflammatory diseases. *Front. Immunol.* **14**, 1265404 (2023).
- 776 103. Hao, Q., Lu, H. & Zhou, X. A potential synthetic lethal strategy with PARP inhibitors:
777 perspective on 'Inactivation of the tumor suppressor p53 by long noncoding RNA RMRP'. *J. Mol.*
778 *Cell. Biol.* **13**, 690-692 (2021).
- 779 104. Huang, R. *et al.* The p53/RMRP/miR122 signaling loop promotes epithelial-mesenchymal
780 transition during the development of silica-induced lung fibrosis by activating the notch pathway.
781 *Chemosphere* **263**, 128133 (2021).
- 782 105. Wolf, C. *et al.* UNC93B1 variants underlie TLR7-dependent autoimmunity. *Sci. Immunol.*,
783 eadi9769 (2024).
- 784 106. He, Z., Ye, S., Xing, Y., Jiu, Y. & Zhong, J. UNC93B1 curbs cytosolic DNA signaling by
785 promoting STING degradation. *Eur. J. Immunol.* **51**, 1672-1685 (2021).

- 786 107. Zhu, H., Zhang, R., Yi, L., Tang, Y. & Zheng, C. UNC93B1 attenuates the cGAS-STING
787 signaling pathway by targeting STING for autophagy-lysosome degradation. *J. Med. Virol.* **94**,
788 4490-4501 (2022).
- 789 108. Ciężyńska, M. *et al.* The Role of NLRP1, NLRP3, and AIM2 Inflammasomes in Psoriasis:
790 Review. *Int. J. Mol. Sci.* **22**, 5898. doi: 10.3390/ijms22115898 (2021).
- 791 109. Docherty, C. A. *et al.* A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the
792 treatment of inflammatory diseases. *Clin. Transl. Immunology* **12**, e1455 (2023).
- 793 110. Miyashita, Y. *et al.* TICAM-1/TRIF associates with Act1 and suppresses IL-17 receptor-
794 mediated inflammatory responses. *Life. Sci. Alliance* **5**, e202101181. doi:
795 10.26508/lsa.202101181. Print 2022 Feb (2021).
- 796 111. Jensen, L. T., Attfield, K. E., Feldmann, M. & Fugger, L. Allosteric TYK2 inhibition:
797 redefining autoimmune disease therapy beyond JAK1-3 inhibitors. *EBioMedicine* **97**, 104840
798 (2023).
- 799 112. Sumpter, R. J. *et al.* Fanconi Anemia Proteins Function in Mitophagy and Immunity. *Cell*
800 **165**, 867-881 (2016).
- 801 113. Xia, M. *et al.* FANCC deficiency mediates microglial pyroptosis and secondary neuronal
802 apoptosis in spinal cord contusion. *Cell. Biosci.* **12**, 82-4 (2022).
- 803 114. Cevher, M. A. *et al.* Nuclear deadenylation/polyadenylation factors regulate 3' processing
804 in response to DNA damage. *EMBO J.* **29**, 1674-1687 (2010).
- 805 115. Gemayel, K. T., Litman, G. W. & Sriaroon, P. Autosomal recessive agammaglobulinemia
806 associated with an IGLL1 gene missense mutation. *Ann. Allergy Asthma Immunol.* **117**, 439-441
807 (2016).
- 808 116. Lu, X. *et al.* MTA2/NuRD Regulates B Cell Development and Cooperates with OCA-B in
809 Controlling the Pre-B to Immature B Cell Transition. *Cell. Rep.* **28**, 472-485.e5 (2019).
- 810 117. Gevezova, M. *et al.* Autistic spectrum disorder (ASD) - Gene, molecular and pathway
811 signatures linking systemic inflammation, mitochondrial dysfunction, transsynaptic signalling,
812 and neurodevelopment. *Brain Behav. Immun. Health.* **30**, 100646 (2023).
- 813 118. Pollina, E. A. *et al.* A NPAS4-NuA4 complex couples synaptic activity to DNA repair.
814 *Nature* **614**, 732-741 (2023).
- 815 119. Zhou, X. *et al.* Integrating de novo and inherited variants in 42,607 autism cases identifies
816 mutations in new moderate-risk genes. *Nat. Genet.* **54**, 1305-1319 (2022).
- 817 120. Wilfert, A. B. *et al.* Recent ultra-rare inherited variants implicate new autism candidate risk
818 genes. *Nat. Genet.* **53**, 1125-1134 (2021).
- 819 121. Fu, J. M. *et al.* Rare coding variation provides insight into the genetic architecture and
820 phenotypic context of autism. *Nat. Genet.* **54**, 1320-1331 (2022).

- 821 122. Mueller, F. S. *et al.* Deficient DNA base-excision repair in the forebrain leads to a sex-
822 specific anxiety-like phenotype in mice. *BMC Biol.* **20**, 170-1 (2022).
- 823 123. Shen, X. *et al.* The role of Gadd45b in neurologic and neuropsychiatric disorders: An
824 overview. *Front. Mol. Neurosci.* **15**, 1021207 (2022).
- 825 124. Dileep, V. *et al.* Neuronal DNA double-strand breaks lead to genome structural variations
826 and 3D genome disruption in neurodegeneration. *Cell* **186**, 4404-4421.e20 (2023).
- 827 125. Yang, C. *et al.* Expression signature of inflammation-associated long non-coding RNAs in
828 adult-onset Still's disease. *Clin. Exp. Rheumatol.* **39 Suppl 132**, 67-74 (2021).
- 829 126. Jaber, S., Toufektchan, E., Lejour, V., Bardot, B. & Toledo, F. p53 downregulates the
830 Fanconi anaemia DNA repair pathway. *Nat. Commun.* **7**, 11091 (2016).
- 831 127. Rakotopare, J. & Toledo, F. p53 in the Molecular Circuitry of Bone Marrow Failure
832 Syndromes. *Int. J. Mol. Sci.* **24**, 14940. doi: 10.3390/ijms241914940 (2023).
- 833 128. Parvin, S. *et al.* ATM depletion induces proteasomal degradation of FANCD2 and
834 sensitizes neuroblastoma cells to PARP inhibitors. *BMC Cancer* **23**, 313-y (2023).
- 835 129. Ishiai, M. Regulation of the Fanconi Anemia DNA Repair Pathway by Phosphorylation and
836 Monoubiquitination. *Genes (Basel)* **12**, 1763. doi: 10.3390/genes12111763 (2021).
- 837 130. Tammimies, K. Genetic mechanisms of regression in autism spectrum disorder. *Neurosci.*
838 *Biobehav. Rev.* **102**, 208-220 (2019).
- 839 131. Golla, S. & Sweeney, J. A. Corticosteroid therapy in regressive autism: Preliminary findings
840 from a retrospective study. *BMC Med.* **12**, 79-79 (2014).
- 841 132. Rossignol, D. A. & Frye, R. E. A Systematic Review and Meta-Analysis of Immunoglobulin
842 G Abnormalities and the Therapeutic Use of Intravenous Immunoglobulins (IVIG) in Autism
843 Spectrum Disorder. *J. Pers. Med.* **11**, 488. doi: 10.3390/jpm11060488 (2021).
- 844 133. Hopfner, K. & Hornung, V. Molecular mechanisms and cellular functions of cGAS-STING
845 signalling. *Nat. Rev. Mol. Cell Biol.* **21**, 501-521 (2020).
- 846 134. Phelan, T., Little, M. A. & Brady, G. Targeting of the cGAS-STING system by DNA viruses.
847 *Biochem. Pharmacol.* **174**, 113831 (2020).
- 848 135. Fan, Y. M., Zhang, Y. L., Luo, H. & Mohamud, Y. Crosstalk between RNA viruses and DNA
849 sensors: Role of the cGAS-STING signalling pathway. *Rev. Med. Virol.* **32**, e2343 (2022).
- 850 136. Wang, C. *et al.* Ultrasound-responsive low-dose doxorubicin liposomes trigger
851 mitochondrial DNA release and activate cGAS-STING-mediated antitumour immunity. *Nat.*
852 *Commun.* **14**, 3877-x (2023).
- 853 137. Kim, J., Kim, H. & Chung, J. H. Molecular mechanisms of mitochondrial DNA release and
854 activation of the cGAS-STING pathway. *Exp. Mol. Med.* **55**, 510-519 (2023).

- 855 138. West, A. P. *et al.* Mitochondrial DNA stress primes the antiviral innate immune response.
856 *Nature* **520**, 553-557 (2015).
- 857 139. Lammert, C. R. *et al.* AIM2 inflammasome surveillance of DNA damage shapes
858 neurodevelopment. *Nature* **580**, 647-652 (2020).
- 859 140. Dawson, R. E. *et al.* The cytosolic DNA sensor AIM2 promotes Helicobacter-induced
860 gastric pathology via the inflammasome. *Immunol. Cell Biol.* **101**, 444-457 (2023).
- 861 141. Vinuesa, C. G., Grenov, A. & Kassiotis, G. Innate virus-sensing pathways in B cell
862 systemic autoimmunity. *Science* **380**, 478-484 (2023).
- 863 142. Hu, Y. *et al.* Emerging role of the cGAS-STING signaling pathway in autoimmune
864 diseases: Biologic function, mechanisms and clinical prospection. *Autoimmun. Rev.* **21**, 103155
865 (2022).
- 866 143. Kivanc, D. & Dasdemir, S. The relationship between defects in DNA repair genes and
867 autoinflammatory diseases. *Rheumatol. Int.* **42**, 1-13 (2022).
- 868 144. Miner, J. J. & Fitzgerald, K. A. A path towards personalized medicine for autoinflammatory
869 and related diseases. *Nat. Rev. Rheumatol.* **19**, 182-189 (2023).
- 870 145. Li, R. *et al.* cGAS/STING signaling in the regulation of rheumatoid synovial aggression.
871 *Ann. Transl. Med.* **10**, 431-4533 (2022).
- 872 146. Hagiwara, A. M., Moore, R. E., Wallace, D. J., Ishimori, M. & Jefferies, C. A. Regulation of
873 cGAS-STING Pathway - Implications for Systemic Lupus Erythematosus. *Rheumatol. Immunol.*
874 *Res.* **2**, 173-184 (2021).
- 875 147. Wobma, H., Shin, D. S., Chou, J. & Dedeoğlu, F. Dysregulation of the cGAS-STING
876 Pathway in Monogenic Autoinflammation and Lupus. *Front. Immunol.* **13**, 905109 (2022).
- 877 148. Iourov, I. Y. *et al.* Causes and Consequences of Genome Instability in Psychiatric and
878 Neurodegenerative Diseases. *Mol. Biol. (Mosk)* **55**, 42-53 (2021).
- 879 149. Loncharich, M. F. & Anderson, C. W. Interferon Inhibition for Lupus with Anifrolumab:
880 Critical Appraisal of the Evidence Leading to FDA Approval. *ACR Open Rheumatol.* **4**, 486-491
881 (2022).
- 882 150. Weckerle, C. E. *et al.* Network analysis of associations between serum interferon- α activity,
883 autoantibodies, and clinical features in systemic lupus erythematosus. *Arthritis Rheum.* **63**,
884 1044-1053 (2011).
- 885 151. Nikolaidou, A., Beis, I., Dragoumi, P. & Zafeiriou, D. Neuropsychiatric manifestations
886 associated with Juvenile Systemic Lupus Erythematosus: An overview focusing on early
887 diagnosis. *Brain Dev.* (2023).

- 888 152. Van der Heijden, H. *et al.* Implications of Inflammatory Processes on a Developing Central
889 Nervous System in Childhood-onset Systemic Lupus Erythematosus. *Arthritis Rheumatol.*
890 (2023).
- 891 153. Ferecskó, A. S. *et al.* STING-Triggered CNS Inflammation in Human Neurodegenerative
892 Diseases. *Biomedicines* **11**, 1375. doi: 10.3390/biomedicines11051375 (2023).
- 893 154. Gulen, M. F. *et al.* cGAS-STING drives ageing-related inflammation and
894 neurodegeneration. *Nature* **620**, 374-380 (2023).
- 895 155. Chen, K. *et al.* cGAS-STING-mediated IFN-I Response in Host Defense and
896 Neuroinflammatory Diseases. *Curr. Neuropharmacol.* **20**, 362-371 (2022).
- 897 156. Beesetti, S. *et al.* FANCL supports Parkin-mediated mitophagy in a ubiquitin ligase-
898 independent manner. *Biochim. Biophys. Acta Mol. Basis Dis.* **1868**, 166453 (2022).
- 899 157. Luzwick, J. W. *et al.* MRE11-dependent instability in mitochondrial DNA fork protection
900 activates a cGAS immune signaling pathway. *Sci. Adv.* **7**, eabf9441 (2021).
- 901 158. Habibi, P. *et al.* Effect of heat stress on DNA damage: a systematic literature review. *Int. J.*
902 *Biometeorol.* **66**, 2147-2158 (2022).
- 903 159. Couillin, I. & Riteau, N. STING Signaling and Sterile Inflammation. *Front. Immunol.* **12**,
904 753789 (2021).
- 905 160. Yang, J. *et al.* STING in tumors: a focus on non-innate immune pathways. *Front. Cell. Dev.*
906 *Biol.* **11**, 1278461 (2023).
- 907 161. He, X. *et al.* IUPHAR ECR review: The cGAS-STING pathway: novel functions beyond
908 innate immune and emerging therapeutic opportunities. *Pharmacol. Res.*, 107063 (2024).
- 909 162. Xun, J. *et al.* A conserved ion channel function of STING mediates noncanonical
910 autophagy and cell death. *EMBO Rep.* (2024).

911

912 **Acknowledgments**

913 H.M.L. is supported by the National Institute of Child Health and Human Development
914 NIH/NICHD; P30 HD071593 to the Albert Einstein College of Medicine's Rose F. Kennedy
915 Intellectual and Developmental Disabilities Research Center, and the National Institute of
916 Mental Health, R21MH131740. The Lachman lab also receives support from the Janice C.
917 Blanchard Family Fund and the iPS Cell Research for Ryan Stearn Fund. This work was funded
918 by grants to the J.L.C Swedish Research Council (Grant No. 2019-06082). P.J. van der Spek is
919 supported by EU H2020 grants, an ImmunAID grant (ID: 7792950), and a
920 MOODSTRATIFICATION grant (ID: 754740). The Bioinformatics infrastructure and team are

921 supported by grants from KWF, NWO/ZonMW, and the Dutch Heart Foundation through the
922 BDVA-initiated H2020 Bigmedilytics program on Personalized Medicine. Janet Cunningham is a
923 Gullstrand Fellow at Uppsala University Hospital. Jennifer Frankovich's research is supported
924 by several foundations including the Neuroimmune Foundation, Lucile Packard Foundation for
925 Children's Health, the Dollinger Biomarker Core, Stanford Spark, and collaborations on NIH
926 grants. Funders had no role in study design, data collection and analysis, decision to publish, or
927 preparation of the manuscript. We thank the Albert Einstein College of Medicine Epigenomics
928 Shared Core Facility RRID: SCR_023284 for Library preparation, QC, and sequencing, and
929 Yongmei Zhao for technical assistance with the library preps. The authors want to thank the
930 participating families.

931

932 **Author contributions**

933 J.L.C. co-wrote the paper, and was involved in the study concept and design; J.F. contributed
934 cases, provided genetic data for cases 16, and 17, and co-wrote the manuscript); R.A.B. carried
935 out WES on case 10); E.P. processed DNA, validated variants, edited manuscript, created
936 figures 1,3; R.F.A. validated variants; N.C.S. contributed case 16; S.B.M. made the WES library
937 for case 10; H.D. involved in study concept; J.M. validated variants); J.E. validated variants;
938 J.M.S. validated variants carried out Alphasense analysis; G.L. contributed case 1, edited
939 manuscript); S.M.A.S. bioinformatics of variants, created Figure 4; S.S. edited manuscript;
940 P.J.S. study concept and design, bioinformatics; H.M.L.co-wrote paper, study concept and
941 design, analyzed variants, confirmed diagnoses, supervised study. All authors reviewed the
942 manuscript.

943

944 **Data availability statement**

945 Variants reported in this paper will be submitted to ClinVar. WES data on case 10 will be made
946 available at GenBank ®

947

948 **Competing interests**

949 J.L.C. has received lecturing fees from Otsuka Pharma Scandinavia, Janssen-Cilag AB and H.
950 Lundbeck AB.

951

952 **Figure Legends**

953 **Figure 1. p53 DNA repair pathway.** A simplified depiction showing the regulation of p53 tumor
954 suppressor activity by phosphorylation triggered by ATM, ATR, CHK1, and CHK2 kinases, and

955 dephosphorylation by PPM1D. P53 activation can induce apoptosis or cell cycle arrest, which
956 will eliminate DNA-damaged cells or provide an opportunity to repair the damage, respectively.
957 Loss of function mutations in *ATM* or gain of function mutations in *PPM1D*, such as those found
958 in patients with acute neuropsychiatric decompensation in cases 1-7, would be expected to lead
959 to a decrease in p53 activity.

960 **Figure 2. Fanconi Core Complex.** The Fanconi Core Complex of proteins repairs interstrand
961 crosslink breaks (Figure adapted from reference 49). The letters are abbreviations for the
962 Fanconi complex proteins (i.e., “A” is FANCA; “E” is FANCE, etc.). Monoubiquitinated (Ub)
963 FANCD2 and FANCI form a dimer that binds to crosslink repair sites, which leads to the
964 recruitment of nucleases that repair the DNA lesion (reference 53). All of the Fanconi complex
965 genes described in this paper are depicted in bold type (FANCE, SLX4, FANCE, and FANCA).
966 Interactions between Fanconi proteins with ATM/ATR are shown. The image was generated
967 using biorender <https://www.biorender.com/>).

968 **Figure 3. Protein-Protein Interaction Network: STRING.** A connectivity network was
969 generated for the candidate genes using IPA software. Central to the network are ATM and p53.
970 Genes described in the paper that do not fit into the connectivity network are not shown (C7,
971 DBH, SLC13AS, SRPK3, NLRX1, MTO1, CACNA1H, CACNA1S, CLPB, AHNAK2). SLX4 =
972 FANCA/SLX4, TP53=p53, and TP53BP1 = 53BP1.

973 **Supplementary Data**

974 **Supplementary Methods.** An expanded description of the methods and primers used for
975 Sanger DNA sequencing.

976 **Supplementary Table.** Description of additional gene variants found upon whole exome
977 sequencing or the analysis of gene panels.


978 **Supplementary Figure. RMRP secondary structures.** The RNAfold web server was used to
979 predict secondary structures for wild-type and mutant (c. C126T) RMRP RNAs. Differences
980 between the two, especially in the centroid secondary structures, are seen.


981

Phosphorylation →
Dephosphorylation —|

medRxiv preprint doi: <https://doi.org/10.1101/2024.02.20.24302984>; this version posted February 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

DNA Damage ⚡





Case	Family	Age*	Gene	Dx	Variant	Type	CADD	ClinVar	AlphaMissense	Inheritance	MAF	Map position hg38	rs number	Additional rare and ultrarare variants	Genome sequencing	Validation
1	N/A	16-20	PPM1D	JdVS, AR, PANS	c.1535delA, p.Asn512fs	frameshift	N/A	pathogenic	N/A	de novo	0.00002	chr17:60663013	rs763475304	CSNK1a1, SRPK3, SLC13A5, CACNA1S	Gene Dx (WES)	yes
2	N/A	6 to 10	PPM1D	JdVS, AR	c.1537G>T, p.Gly257E	nonsense	39	uncertain significance	N/A	de novo	7E-06	chr17:60663017	rs759350701	none reported	NHS North West (NDI panel)	no
3	N/A	11 to 15	ATM	PANS	c.7317_7520del, p.Arg2306R	frameshift	N/A	pathogenic	N/A	parent	8E-06	chr11:108333342-1083333548	rs307781905	CACNA1H, AHHA42	Baylor Genetics (WES)	no
4	1	6 to 10	ATM	ASD, AR, PANS	c.8418-5_8418-8delGTGA	splice donor	N/A	pathogenic	N/A	parent	4E-06	chr11:108343272-108343479	rs730881295	RNASEH2B, RAG2, C7, NO D2, SP110	Invitae Immunodeficiency Panel	yes
5	1	11 to 15	ATM	ASD, AR, PANS	c.8418-5_8418-8delGTGA	splice donor	N/A	pathogenic	N/A	parent	4E-06	chr11:108343272-108343479	rs730881295	RNASEH2B, RAG2, NO D2, rs529640820	Sanger sequencing of case 4 variants	yes
6	1	6 to 10	ATM	ASD, AR, PANS	c.8418-5_8418-8delGTGA	splice donor	N/A	pathogenic	N/A	parent	4E-06	chr11:108343272-108343479	rs730881295	RNASEH2B, C7, NO D2, rs529640820	Gene Dx (WES)	yes
7	1	6 to 10	ATM	ASD, AR, PANS	c.8418-5_8418-8delGTGA	splice donor	N/A	pathogenic	N/A	parent	4E-06	chr11:108343272-108343479	rs730881295	RAG2, NO D2, rs140716236, SP110	Sanger sequencing of case 4 variants	yes
8	2	0-5	ATR	ASD, PANS, AE	c.2507A>T, p.Asp836Val	missense	24	not found	benign, 0.095	parent	unknown	chr3:142,553,850	novel	CENPI, NLRX1, DBH, CACNA1S, CLPB	Courtagen Diagnostics Laboratory (WES)	yes
9	2	0-5	ATR	ASD, PANS, AR	c.2507A>T, p.Asp836Val	missense	24	not found	benign, 0.095	parent	unknown	chr3:142,553,850	novel	CENPI, NLRX1, DBH, CACNA1S, CLPB	Courtagen Diagnostics Laboratory (WES)	yes
10	N/A	0-5	S3BP1	DD, AR, PANS	c.6330T>T, p.Asp1103Y	missense	21.7	not found	benign, 0.1176	unknown	0.00002	chr15:14432462	rs51038749	MEI1, RMT2D, MTD1	Emmett Epigenetics Shared Facility (WES)	yes
11	3	0-5	FANCE	CVID, PANS	c.127G>A, p.Gly43Ser	missense	23.1	uncertain significance	ambiguous, 0.4766	parent	unknown	chr6:35452572	rs92819655	VPS13B	Invitae Immunodeficiency Panel	yes
12	3	0-5	FANCE	CVID, DD, AE	c.127G>A, p.Gly43Ser	missense	23.1	uncertain significance	ambiguous, 0.4766	parent	unknown	chr6:35452572	rs92819655	VPS13B, THRAP3, NO D2	Invitae Immunodeficiency Panel	yes
13	N/A	11 to 15	FANCI	AE, PANS	c.1461T>A, p.Tyr487Ter	nonsense	37	pathogenic/likely pathogenic	N/A	unknown	0.00003	chr15:89281149	rs769248873	FANCP/SXL4, UGA	Invitae Immunodeficiency Panel	no
14	4	6 to 10	FANCP	CVID, PANS, AE	c.2623G>A, p.Glu875Lys	missense	14.15	not found	benign, 0.0771	unknown	1.6E-05	chr16:3590914	rs924466221	RMRP, MEV, TNFRSF13B, DOC18	Invitae Immunodeficiency Panel	no
15	4	6 to 10	FANCP	CVID, AE	c.2623G>A, p.Glu875Lys	missense	14.15	not found	benign, 0.0771	unknown	1.6E-05	chr16:3590914	rs924466221	RMRP, MEV, TNFRSF13B, DOC18	Invitae Immunodeficiency Panel	no
16	N/A	6 to 10	FANCA	PANS	c.1771C>G, p.Arg591Gly	missense	21.9	uncertain significance	pathogenic, 0.6394	unknown	0.00006	chr16:89778848	rs759380264	UNC93B1, NLRP1, TICAM1, TYK2, TCN2	Invitae Immunodeficiency and Ciliary Dyskinesia Panel	no
17	N/A	0-5	FANCC	PANS	c.883dup, p.Asp295Glyfs*2	frameshift	N/A	pathogenic	N/A	unknown	unknown	chr9:95126542	rs182600748	KLHL1, PARN	Invitae AAS, IEIC, MIBD	no

Table. Description of all primary DNA repair variants. *Age range at diagnosis; Dx: diagnosis (JdVS: Jansen de Vries Syndrome, AR: acute regression, PANS: pediatric acute-onset neuropsychiatric syndrome, AE: autoimmune encephalitis, DD: developmental delay, CVID: common variable immune deficiency); variant shows the cDNA and amino acid changes; type shows how the mutation affects gene function; CADD: Combined Annotation score; N/A not available. ClinVar is the predicted pathogenicity based on the ClinVar database; AlphaMissense is the predicted pathogenicity based on amino acid change (see main text); Inheritance pattern shows that the variant in question was either de novo or transmitted from a parent. The sex of the parent was omitted to maintain anonymity; MAF: Minor allele frequency; Map position shows coordinates of variants based on hg38 build; rs number is based on SNP database; Additional variants were found in each case (see Supplemental table for descriptions). Genome sequencing shows the different methods used to detect variants, For case 17, Invitae AAS, IEIC, and MIBD panels are Autoinflammatory and Autoimmunity Syndromes, Inborn errors of immunity and Cytopenia, and Monogenic Inflammatory Bowel Disease, respectively.